Ibrutinib

Ibrutinib Reactions 1680, p163 - 2 Dec 2017 Various toxicities: 2 case reports In a case series, two patients were described, out of whom a 79-year-old woman developed nail plate abnormalities, ecchymoses and actinic keratosis, and a 53-year-old man developed nail plate abnormalities, desquamative dermatitis with red-brown macules and petechiae during treatment with ibrutinib [not all outcomes stated]. Case 1: A 79-year-old woman, who had a history of chronic lymphocytic leukaemia (CLL), was started on systemic treatment with oral ibrutinib 420mg daily. Within six months from the start of ibrutinib, she observed changes in the texture and appearance of her nails. Cutaneous skin examination showed significant changes of her fingernails and toenails with brittle and fragile nature. Therefore, she was started on biotin. In addition to the nail changes, she also developed ecchymoses on her arms and legs. She had ten actinic keratosis, which was treated with cryotherapy. Three months after the start of biotin, her toenails brittleness improved. However, new ecchymoses continued to grow on her extremities. Case 2: A 53-year-old man, who had a history of CLL, was started on systemic treatment with oral ibrutinib 420mg daily. He also received venetoclax (ABT199). Within four months from the start of ibrutinib, he observed changes in the appearance of his nails. Cutaneous skin examination showed significant changes of the nails on finger, thumb and toe with brittle and fragile nature. Therefore, he was started on biotin. In addition to the nail changes, he also developed ecchymoses desquamative dermatitis with red-brown macules. He also had petechiae on the tip of the left great toe. Author comment: "Ibrutinib, a tyrosine kinase inhibitor, is a novel therapy for chronic lymphocytic leukemia that has been associated with nail plate abnormalities." "Bruising, hair changes and nail plate abnormalities, pruritus and rashes are the most common cutaneous side effects of ibrutinib; less common skin adverse events include purpuric painful nodules and pyoderma gangrenosum." Heldt Manica LA, et al. Ibrutinib-Associated Nail Plate Abnormalities: Case Reports and Review. Drug Safety - Case Reports 4: No. 15, Dec 2017. Available from: URL: http://doi.org/10.1007/s40800-017-0060-1 - USA 803284587 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Ibrutinib

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/ibrutinib-ODq7tEr002
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39094-2
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p163 - 2 Dec 2017 Various toxicities: 2 case reports In a case series, two patients were described, out of whom a 79-year-old woman developed nail plate abnormalities, ecchymoses and actinic keratosis, and a 53-year-old man developed nail plate abnormalities, desquamative dermatitis with red-brown macules and petechiae during treatment with ibrutinib [not all outcomes stated]. Case 1: A 79-year-old woman, who had a history of chronic lymphocytic leukaemia (CLL), was started on systemic treatment with oral ibrutinib 420mg daily. Within six months from the start of ibrutinib, she observed changes in the texture and appearance of her nails. Cutaneous skin examination showed significant changes of her fingernails and toenails with brittle and fragile nature. Therefore, she was started on biotin. In addition to the nail changes, she also developed ecchymoses on her arms and legs. She had ten actinic keratosis, which was treated with cryotherapy. Three months after the start of biotin, her toenails brittleness improved. However, new ecchymoses continued to grow on her extremities. Case 2: A 53-year-old man, who had a history of CLL, was started on systemic treatment with oral ibrutinib 420mg daily. He also received venetoclax (ABT199). Within four months from the start of ibrutinib, he observed changes in the appearance of his nails. Cutaneous skin examination showed significant changes of the nails on finger, thumb and toe with brittle and fragile nature. Therefore, he was started on biotin. In addition to the nail changes, he also developed ecchymoses desquamative dermatitis with red-brown macules. He also had petechiae on the tip of the left great toe. Author comment: "Ibrutinib, a tyrosine kinase inhibitor, is a novel therapy for chronic lymphocytic leukemia that has been associated with nail plate abnormalities." "Bruising, hair changes and nail plate abnormalities, pruritus and rashes are the most common cutaneous side effects of ibrutinib; less common skin adverse events include purpuric painful nodules and pyoderma gangrenosum." Heldt Manica LA, et al. Ibrutinib-Associated Nail Plate Abnormalities: Case Reports and Review. Drug Safety - Case Reports 4: No. 15, Dec 2017. Available from: URL: http://doi.org/10.1007/s40800-017-0060-1 - USA 803284587 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off